University of Alberta
- Country
- 🇨🇦Canada
- Ownership
- Private
- Established
- 1908-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.ualberta.ca
Onco-Innovations Partners with University of Alberta to Advance PNKP Inhibitor Research for Glioblastoma Treatment
Onco-Innovations has entered into a research agreement with the University of Alberta and Cross Cancer Institute to expand preclinical studies of its PNKP inhibitor technology for hard-to-treat cancers, beginning with glioblastoma multiforme.
World-First Clinical Trial Demonstrates Exercise Significantly Improves Colon Cancer Survival
A groundbreaking 17-year international clinical trial involving 889 colon cancer patients shows that structured exercise programs reduce cancer recurrence risk by 28% and death risk by 37%.
Onco-Innovations Initiates Manufacturing of PNKP Inhibitor for Preclinical Testing
Onco-Innovations has partnered with Dalton Pharma Services to begin manufacturing 50 grams of their proprietary PNKP inhibitor A83B4C63 for preclinical testing.
University of Alberta's Novel Cancer Drug Zelenirstat Receives FDA Fast-Track Designation
University of Alberta researchers have developed Zelenirstat, an innovative oral cancer medication that works by preventing cancer cell spread and starving tumors.